Fig. 4From: Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studiesOdds ratios of changes in SF-36v2 PCS and MCS scores at various time points. Odds of (a) a drop in SF-36v2 PCS scores greater than the MIC at the end of AVT treatment; (b) a return to baseline levels in SF-36v2 PCS scores; (c) a return to baseline levels in SF-36v2 PCS (submission scoring) scores; (d) a drop in SF-36v2 MCS scores greater than the MIC at the end of AVT treatment; (e) a return to baseline levels in SF-36v2 MCS scores; and (f) a return to baseline levels in SF-36v2 MCS (submission scoring) scores. AVT, antiviral therapy; CD, cumulative dose; EVR, early virologic response; IFN, interferon; MELD, Model for End-Stage Liver Disease; MIC, minimally important change; SF-36v2, Short-Form 36 Health Survey version 2; SVR, sustained virologic responseBack to article page